Mankind Pharma Limited
Mainboard₹14,040 / 13 Shares
IPO Details
Mankind Pharma Limited IPO is priced between ₹1026-1080 per equity share, with a face value of ₹1 per share. The company's equity shares will be listed on the Mainboard, and KFin Technologies Limited is managing the issue as the registrar.
The IPO bidding period opened on 25 Apr, 2023, and closed on 27 Apr, 2023. The allotment results will be announced on 3 May, 2023, with a tentative listing date set for 9 May, 2023.
The total issue comprises 40,058,844 shares, amounting to ₹4,326.36 Cr Offer for Sale.
Mankind Pharma Limited IPO Highlights
| IPO Date | Listing Date | Face Value | Price Band | Lot Size | Fresh Issue | Offer for Sale | Listing At |
|---|---|---|---|---|---|---|---|
| Apr 25, 2023 - Apr 27, 2023 | 9 May, 2023 | ₹1 Per Equity Share | ₹1026-1080 per equity share | - | Shares | - | BSE, NSE |
Mankind Pharma Limited IPO Timeline
Issue Price
₹1026-1080 per equity shareFace Value
₹1 Per Equity ShareListing at Group
BSE, NSERegistrar
KFin Technologies LimitedMarket Lot
13 Shares (₹14,040/-)sHNI : 195 Shares (₹2,10,600/-)bHNI : 936 Shares (₹10,10,880/-)Lead Manager
Kotak Mahindra Capital CompanyAxis Capital LimitedIIFL Securities LtdJefferies India Private LimitedJ.P. Morgan India Private LimitedIssue Size
40,058,844 shares(aggregating up to ₹4,326.36 Cr Offer for Sale)Retail Portion
35% (Number of Retail Applications : 10,78,500 Approx),(Number of sHNI Applications : 10,270 Approx),(Number of bHNI Applications : 20,540 Approx)Subscription
15.32 timesMankind Pharma Limited IPO Financial Information
| Period Ended | Assets | Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 31 Dec 22 | 9273.75 | 6777.82 | 1015.98 | - | - | - |
| 31 Mar 22 | 9147.74 | 7977.58 | 1452.96 | - | - | - |
| 31 Mar 21 | 6372.63 | 6385.38 | 1293.03 | - | - | - |
| 31 Mar 20 | 5073.29 | 5975.65 | 1056.15 | - | - | - |
All values are in ₹ Cr.
About Company
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.
The company has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among these.
The company has its presence in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market (IPM). Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.
The company has been awarded The Best of Bharat Awards 2022 by exchange4media in the year 2022, Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing, and Silver Award for Good Health Brand at IHW Awards 2021 in the year 2021, Best Condom Brand of the Year award at Sex Brand Awards Pharma OTC Company of the Year Award at Pharma Excellence Awards 2018, Award for Best Design in Healthcare at Healthcare Leadership Awards 2017, and Amity HR Excellence Award for Performance Management at the 8th Global HR Summit 2011.
Mankind Pharma Limited IPO Subscription Details
| As on | QIB | NII bNII sNII | Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 8,011,769 | 6,008,827 4,005,885 2,002,942 | 14,020,596 | 28,041,192 |
| Day 1 - 25-04-23 05:00 PM | 0.08 x | 0.33 0.37 x 0.25 x | 0.10 x | 0.14 x |
| Day 2 - 26-04-23 05:00 PM | 1.86 x | 1.02 1.21 x 0.64 x | 0.25 x | 0.87 x |
| Day 3 - 27-04-23 05:00 PM | 49.16 x | 3.80 4.99 x 1.41 x | 0.92 x | 15.32 x |
Mankind Pharma Limited IPO - Issue Objectives
- All of the offer proceeds will be received by the selling shareholders in proportion to the offered shares that each selling shareholder sold as part of the offer; the company will not receive any of the offer proceeds.